Glypican‑3 expression in malignant small round cell tumors

Shibui,Yuichi; Miyoshi,Kina; Kohashi,Kenichi; Kinoshita,Yoshiaki; Kuda,Masaaki; Yamamoto,Hidetaka; Taguchi,Tomoaki; Oda,Yoshinao

doi:10.3892/ol.2019.9976

Glypican‑3 expression in malignant small round cell tumors

Authors:
- Yuichi Shibui
- Kina Miyoshi
- Kenichi Kohashi
- Yoshiaki Kinoshita
- Masaaki Kuda
- Hidetaka Yamamoto
- Tomoaki Taguchi
- Yoshinao Oda
View Affiliations

Affiliations: Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812‑8582, Japan, Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812‑8582, Japan
Published online on: January 25, 2019 https://doi.org/10.3892/ol.2019.9976
Pages: 3523-3528

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant small round cell tumors usually progress rapidly and show resistance to chemotherapy, and it is often difficult to make a definitive diagnosis based on their histological morphology. Glypican‑3 (GPC3) is a highly tumor‑specific antigen, and the overexpression of GPC3 was reported in many pediatric and adult malignancies. In the present study, we investigated the GPC3 expression in pediatric malignant small round cell tumors to assess its role in the differential diagnosis of the tumors. Immunohistochemistry was performed to assess the expression of GPC3 in samples from 84 rhabdomyosarcomas (RMSs; 44 alveolar and 40 embryonal RMSs), 62 Ewing sarcomas (EWSs), 35 neuroblastomas (NBs) and two desmoplastic small round cell tumors (DSRCTs). We performed a reverse transcription‑quantitative polymerase chain reaction for GPC3 to determine the GPC3 mRNA expression in samples from 66 frozen tumors (23 RMSs, 28 EWSs and 15 NBs). The serum expression levels of GPC3 were analyzed in pre‑operative blood samples from two RMS and eight NB patients. In total, 25% (21/84) of the RMSs and 3% (1/35) of the NBs exhibited a focal expression of GPC3, whereas, the other specimens showed no GPC3 expression. The GPC3 mRNA expression level of the RMSs with positive GPC3 expression (n=6) was significantly higher compared with the RMSs without such expression (n=17). A total of two cases of NB showed high serum levels of GPC3, but neither tumor showed immunoreactivity for GPC3. The immunohistochemical overexpression of GPC3 may be a candidate ancillary parameter in the differential diagnosis of RMS from EWS and DSRCT.

View Figures

View References

1	Filmus J: Glypicans in growth control and cancer. Glycobiology. 11:19R–23R. 2001. View Article : Google Scholar : PubMed/NCBI
2	Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L and de Kier Joffé EB: Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol. 23:1333–1340. 2008.PubMed/NCBI
3	DeBaun MR, Ess J and Saunders S: Simpson Golabi Behmel syndrome: Progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. Mol Genet Metab. 72:279–286. 2001. View Article : Google Scholar : PubMed/NCBI
4	Lapunzina P: Risk of tumorigenesis in overgrowth syndromes: A comprehensive review. Am J Med Genet C Semin Med Genet. 137C:53–71. 2005. View Article : Google Scholar : PubMed/NCBI
5	Schirwani S, Novelli A, Digilio MC, Bourn D, Wilson V, Roberts C, Dallapiccola B and Hobson E: Duplications of GPC3 and GPC4 genes in symptomatic female carriers of simpson-golabi-behmel syndrome type 1. Eur J Med Genet pii. S1769-7212:30203–30209. 2018.
6	Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, et al: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 306:16–25. 2003. View Article : Google Scholar : PubMed/NCBI
7	Levy M, Trivedi A, Zhang J, Miles L, Mattis AN, Kim GE, Lassman C, Anders RA, Misdraji J, Yerian LM, et al: Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol. 43:695–701. 2012. View Article : Google Scholar : PubMed/NCBI
8	Xing XL, Qin H, Yan SQ, Zhou LS, Chen P and Zhao D: Expression of glypican-3 is highly associated with pediatric hepatoblastoma: A systemic analysis. Asian Pac J Cancer Prev. 16:1029–1031. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kinoshita Y, Tanaka S, Souzaki R, Miyoshi K, Kohashi K, Oda Y, Nakatsura T and Taguchi T: Glypican 3 expression in pediatric malignant solid tumors. Eur J Pediatr Surg. 25:138–144. 2015.PubMed/NCBI
10	Kohashi K, Nakatsura T, Kinoshita Y, Yamamoto H, Yamada Y, Tajiri T, Taguchi T, Iwamoto Y and Oda Y: Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. Hum Pathol. 44:526–533. 2013. View Article : Google Scholar : PubMed/NCBI
11	Saikali Z and Sinnett D: Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 89:418–422. 2000. View Article : Google Scholar : PubMed/NCBI
12	Ota S, Hishinuma M, Yamauchi N, Goto A, Morikawa T, Fujimura T, Kitamura T, Kodama T, Aburatani H and Fukayama M: Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch. 449:308–314. 2006. View Article : Google Scholar : PubMed/NCBI
13	Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS and Jothy S: Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 21:817–825. 2008. View Article : Google Scholar : PubMed/NCBI
14	Thway K, Selfe J, Missiaglia E, Fisher C and Shipley J: Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas. J Clin Pathol. 64:587–591. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T and Nishimura Y: Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 10:6612–6621. 2004. View Article : Google Scholar : PubMed/NCBI
16	Baer C, Nees M, Breit S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T and Nishimura Y: Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer. 110:687–694. 2004. View Article : Google Scholar : PubMed/NCBI
17	Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, et al: Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin Cancer Res. 18:3686–3696. 2012. View Article : Google Scholar : PubMed/NCBI
18	Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T and Nakatsura T: Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 100:1403–1407. 2009. View Article : Google Scholar : PubMed/NCBI
19	Zhang J, Zhang M, Ma H, Song X, He L, Ye X and Li X: Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. Medicine (Baltimore). 97:e1111302018.
20	Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M and Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer. 103:455–465. 2003. View Article : Google Scholar : PubMed/NCBI
21	Chan ES, Pawel BR, Corao DA, Venneti S, Russo P, Santi M and Sullivan LM: Immunohistochemical expression of glypican-3 in pediatric tumors: An analysis of 414 cases. Pediatr Dev Pathol. 16:272–277. 2013. View Article : Google Scholar : PubMed/NCBI